Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

US Previously Marketed

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Dopamine D1 receptor

6

Dopamine receptor

6

Acetylcholinesterase

3

Butyrylcholinesterase

3

Histamine N-methyltransferase

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

9

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1970

6

1993

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Parkinson's disease

6

Alzheimer’s disease

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

9

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

9

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Hoffman-La Roche

6

Warner-Lambert

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

9

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

9

FDA UNII

9

PUBCHEM

9

SMS_ID

8

EPA CompTox

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTI-PARKINSON DRUGS

3

PSYCHOANALEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DOPAMINERGIC AGENTS

3

ANTI-DEMENTIA DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Dopa and dopa derivatives

3

Anticholinesterases

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 9 of 9 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

LEVODOPA

46627O600J

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

TACRINE

4VX7YNB537

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1993

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Acetylcholinesterase

Histamine N-methyltransferase

Butyrylcholinesterase

Conditions:

Alzheimer’s disease

Tacrine is a parasympathomimetic- a reversible cholinesterase inhibitor that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memor...

y loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine at cholinergic synapses through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, tacrine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that tacrine alters the course of the underlying dementing process. The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine. is used for the palliative treatment of mild to moderate dementia of the Alzheimer's type. Tacrine was marketed under the trade name Cognex. Because of its liver toxicity and attendant requirement for monitoring liver function, tacrine prescriptions dropped after other acetylcholinesterase inhibitors were introduced, and its use has been largely discontinued.

BISMUTH SUBDOPATE

G69RN28K8B

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

FOSLEVODOPA

37NQZ0J76I

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

MELEVODOPA HYDROCHLORIDE

JFU1A8866V

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

MELEVODOPA

M30686U4X4

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

ETILEVODOPA

895X917GYE

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 1970

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D1 receptor

Dopamine receptor

Conditions:

Parkinson's disease

Levodopa (L-DOPA) was first isolated from seedlings of Vicia faba by Marcus Guggenheim in 1913. Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease. Oral levodopa has been wi...

dely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor carbidopa, which reduces many treatment complications, extending its half-life and increasing levodopa availability to the brain. Entacapone, a catechol-O-methyltransferase inhibitor, can also be used to improve the bioavailability of levodopa, especially when used in conjunction with a carbidopa.

TACRINE HYDROCHLORIDE MONOHYDRATE

MQ603P8SBL

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1993

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Acetylcholinesterase

Histamine N-methyltransferase

Butyrylcholinesterase

Conditions:

Alzheimer’s disease

Tacrine is a parasympathomimetic- a reversible cholinesterase inhibitor that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memor...

y loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine at cholinergic synapses through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, tacrine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that tacrine alters the course of the underlying dementing process. The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine. is used for the palliative treatment of mild to moderate dementia of the Alzheimer's type. Tacrine was marketed under the trade name Cognex. Because of its liver toxicity and attendant requirement for monitoring liver function, tacrine prescriptions dropped after other acetylcholinesterase inhibitors were introduced, and its use has been largely discontinued.

TACRINE HYDROCHLORIDE

4966RNG0BU

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1993

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Acetylcholinesterase

Histamine N-methyltransferase

Butyrylcholinesterase

Conditions:

Alzheimer’s disease

Tacrine is a parasympathomimetic- a reversible cholinesterase inhibitor that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memor...

y loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine at cholinergic synapses through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, tacrine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that tacrine alters the course of the underlying dementing process. The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine. is used for the palliative treatment of mild to moderate dementia of the Alzheimer's type. Tacrine was marketed under the trade name Cognex. Because of its liver toxicity and attendant requirement for monitoring liver function, tacrine prescriptions dropped after other acetylcholinesterase inhibitors were introduced, and its use has been largely discontinued.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1